The Global Biotech Race: US and China Are Closer Than Ever
For decades, the United States has been the undisputed global leader in biomedical innovation. From Nobel Prize-winning research to blockbuster drug approvals, American institutions have set the pace for the rest of the world. But a new survey is making it increasingly clear that China is no longer a distant second. According to findings from the Cure Innovation Index, China has closed the gap in significant areas of the biotech pipeline — and in some categories, it has already pulled ahead.
The poll, which surveyed senior leaders across US industry and academia, assessed competitive standing across six key sectors of the biomedical landscape. The results offer a nuanced picture of a rapidly shifting global dynamic — one that should command the attention of policymakers, investors, and scientific leaders alike.
Where China Now Leads: Clinical Development and Supply Chain
Perhaps the most striking headline from the survey is this: China now conducts more clinical drug trials than the United States. That milestone alone signals a dramatic transformation in how China approaches pharmaceutical development. Just two decades ago, China was largely viewed as a manufacturer of generic drugs rather than a pioneer of novel therapies. That perception is now dangerously outdated.
According to the Cure Innovation Index survey, respondents identified China as the clear leader in two out of the six evaluated sectors: clinical development and supply chain management.
Clinical Development
China's dominance in clinical trials is not accidental. The Chinese government has invested heavily in modernizing its regulatory infrastructure, streamlining trial approvals, and incentivizing domestic pharmaceutical companies to pursue innovative drug candidates. The sheer scale of China's population also provides a vast patient pool for trial recruitment, enabling faster enrollment timelines that Western sponsors find increasingly attractive. Chinese contract research organizations (CROs) have matured significantly, offering competitive pricing and improving standards that have drawn global pharmaceutical companies to partner with or conduct trials in China.
Supply Chain
China's grip on the global pharmaceutical supply chain is well established — and the survey confirms that US leaders recognize it. China dominates the production of active pharmaceutical ingredients (APIs), the raw chemical building blocks that go into nearly every drug sold in Western markets. This dependency became a critical vulnerability during the COVID-19 pandemic, prompting calls for supply chain reshoring in the US and Europe. Despite those calls, China's position in this sector remains strong, underpinned by deep manufacturing infrastructure, competitive labor costs, and years of accumulated industrial expertise.
Where the United States Retains Its Edge
Despite China's advances, the survey found that the US continues to lead across four of the six sectors examined, including the arguably more lucrative and strategically important areas of the biotech value chain.
Translational Research and Large-Scale Production
The ability to move an experimental product from the laboratory bench through to large-scale manufacturing is a critical and complex challenge. The US biotech ecosystem — anchored by elite research universities, specialized manufacturing facilities, and a deep bench of experienced bioprocessing talent — still holds a meaningful advantage in this area. Translating a promising compound into a commercially viable product requires not just scientific excellence but engineering ingenuity, regulatory expertise, and process optimization at scale. These capabilities are deeply embedded in the US system in ways that take generations to fully replicate.
Capital and Investment
Access to capital remains one of the most powerful advantages the US biotech sector enjoys. The United States is home to the world's most sophisticated biotech investment ecosystem, encompassing venture capital firms with deep scientific expertise, public markets that provide liquidity through IPOs and follow-on offerings, and a robust network of strategic partnerships with major pharmaceutical companies. In 2024, US biotech companies continued to attract the lion's share of global venture investment, enabling early-stage companies to survive the long and expensive journey from discovery to clinical proof of concept. China has made significant strides in building its own biotech investment infrastructure, but it has not yet matched the depth, diversity, or risk tolerance of US capital markets.
Commercialization
Commercialization — turning an approved drug into a market success — is where the US arguably leads the world by the widest margin. The US pharmaceutical market is the largest and most profitable in the world, driven by a pricing environment that rewards innovation. American companies benefit from sophisticated market access strategies, established relationships with payers and pharmacy benefit managers, and an unparalleled commercial infrastructure. Chinese biotech firms, while increasingly capable at development, still face significant hurdles when attempting to commercialize products in global markets, including navigating FDA approval pathways, building out sales forces, and earning the trust of international prescribers.
Why This Survey Matters for Biotech Strategy
The findings of the Cure Innovation Index survey carry practical implications across multiple stakeholder groups. For US policymakers, the data underscores the urgency of continued investment in biomedical research funding, regulatory modernization, and supply chain resilience. For investors, the survey highlights where the US competitive moat remains deepest — and where it is most at risk of erosion. For pharmaceutical executives, the results reinforce both the opportunity in partnering with Chinese clinical development capabilities and the strategic risk of over-reliance on Chinese supply chains.
It would be a mistake to read this survey as reassuring. The fact that China has already overtaken the US in clinical development and supply chain — two foundational pillars of drug creation — suggests that the gap in remaining sectors could narrow faster than anticipated. Innovation ecosystems compound over time: clinical trial expertise feeds translational research capacity, and supply chain mastery reduces manufacturing costs that can fund further R&D investment.
Looking Ahead: Competition That Could Reshape Medicine
The US-China biotech competition is not simply a story of national rivalry. It is a dynamic that will shape which diseases get prioritized for drug development, where breakthrough therapies originate, and who ultimately controls the infrastructure of global health. The United States has built an extraordinary biomedical enterprise over many decades, and the survey confirms it retains real and substantial advantages. But those advantages are not guaranteed to persist without deliberate effort, sustained investment, and a clear-eyed understanding of where the competitive landscape is shifting.
China is closing in. The question is not whether the US can afford to acknowledge that — it is whether it can move fast enough to respond.